Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 43 - Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development

  • from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
  • Edited by Jeffrey Cummings, University of Nevada, Las Vegas, Jefferson Kinney, University of Nevada, Las Vegas, Howard Fillit
  • Book:
    Alzheimer's Disease Drug Development
    Published online:
    03 March 2022
    Print publication:
    31 March 2022, pp 486-495

  • Summary

    Alzheimer’s disease (AD) is a public health challenge that grows in urgency every year. As the world’s largest dedicated voluntary health organization to AD and related dementia (ADRD), the Alzheimer’s Association has a vision of a world without AD and ADRD. In addition to providing care and support in communities across the United States and actively pursuing advocacy for federal research support and community needs,it is committed to advancing vital research toward methods of treatment, prevention, and a cure. In addition to financial support to researchers worldwide, it promotes the sharing of knowledge and data, gathering key stakeholders form the field, including academia, federal, non-profit and industry to advance research (such as through the Alzheimer’s Association International Conference) and accelerating clinical trial research though Alzheimer’s Association TrialMatc. The Association’s funding expands the full spectrum of research, with focused funding on drug development and early-phase human trials.